Skip to main content

Table 1 Schedule of visits for patients recruited to studies II and III

From: Anticoagulated patient’s perception of their illness, their beliefs about the anticoagulant therapy prescribed and the relationship with adherence: impact of novel oral anticoagulant therapy – study protocol for The Switching Study: a prospective cohort study

Visit 1 (baseline – on VKA)

Visit 2 (1 month into NOAC)

Visit 3 (2 months into NOAC)

Visit 4 (1 year into NOAC)

Full medical and drug history obtained, including calculation of aCHADS2 [44], aCHA2DS2VASc [14], HASBLED [45], the Medication Related Complexity Index (MRCI) [46], SAMe-TT2R2 [26], the Charlson index [47] and whether the patient has symptomatic disease or not

Patient reviewed clinically

Patient reviewed clinically

IPQ/BMQ (NOAC)/ACTS instruments administered

Socio-demographic informationb

Patient self-reported missed doses recorded + pill count

Patient self-reported missed doses recorded + pill count

PTS assessment if DVT patient

Informed written consent

Another 1 month prescription of NOAC given to patient

Another 1 month prescription of NOAC given to patient

Adherence assessment through GP summary care record, patient self-report and the 8-item Morisky Medication Adherence Scale

IPQ/BMQ (warfarin)/ACTS instruments administered

Bloods for UEs/FBC

Bloods for UEs/FBC (if not done at visit 2)

Patient switched to NOAC (1 month prescription)

IPQ/BMQ (NOAC)/ACTS instruments administered

Patient transferred to GP for on-going prescriptions

PTS assessment if DVT patient

PTS assessment if DVT patient

PTS assessment if DVT patient

  1. aonly for patients prescribed anticoagulant therapy in the context of atrial fibrillation
  2. bsocio-demographic information will be obtained from the patient’s medical notes, namely age, gender, post-code, ethnicity